IHMRI’s electrophysiology facility with the new Syncropatch 384 is just days away from operation.
The state-of-the-art patch-clamp robot has been unpacked and is being installed.
The powerful new technology will speed up the process of cell analysis and will significantly reduce lab times for researchers.
“This facility represents a quantum leap in productivity for biosciences in this country which will potentially give the Australian pharmaceutical industry a competitive global edge,” says IHMRI’s CEO/Executive Director, Professor David J. Adams.
Nina Brinkwirth and Kenneth Andersen from Nanion in Munich have been overseeing the installation and conducting technical training of the robot.
“This project places IHMRI at the forefront of cell phenotyping and drug discovery. It is only the second high-throughput automated patch-clamp facility in Australia and, one of only a few in the world,” says Professor David Adams.
The Patch-clamp technique allows scientists to measure the electrical activity in single living cells and their responses to different drugs.
Professor Adams was instrumental in securing Australian Research Council (ARC) funding under the Linkage, Equipment and facilities (LIEF) scheme.
The $443,311 grant covered about half the cost of the machine.
The grant win is a partnership of scientists from IHMRI, the University of Sydney, the University of NSW and the Victor Change Cardiac Research Institute.
More about Professor David J. Adams
Louise Negline, Communications Coordinator
t: 4221 4702
m: 0417 044 867
Top photo: Kenneth Andersen and Nina Brinkwirth from Nanion in Munich are setting up the Syncropatch 384 in IHMRI’s electrophysiology facility.